The Q4 2026 data readouts from BASECAMP (pediatric) and TRAILHEAD (adult) are the next major catalysts. Monitor for enrollment updates and any early efficacy signals from the ongoing trials. The strong cash runway through 2027 removes near-term financing risk, allowing the clinical program to advance without immediate dilution pressure.
Price Chart
Executive Summary
Satellos Bioscience reported Q2 2026 financial results, showing a net loss of $11.7M ($0.56/share) vs $5.6M ($0.39/share) in Q2 2025, driven by increased R&D spending on Phase 2 trials for SAT-3247. The company has $61.8M in cash, sufficient through 2027, and highlighted FDA Fast Track designation for SAT-3247 in DMD, with key catalysts expected in Q4 2026: BASECAMP pediatric data and TRAILHEAD adult study update. The widening loss is expected for a clinical-stage biotech, and the clinical progress and strong cash position are the primary drivers for the stock.
Key Facts
- Net loss for Q2 2026 was $11.7M ($0.56/share), compared to $5.6M ($0.39/share) in Q2 2025.
- Cash, cash equivalents and short-term investments totaled $61.8M as of June 30, 2026, up from $27.7M at Dec 31, 2025.
- FDA granted Fast Track designation to SAT-3247 for Duchenne muscular dystrophy on June 29, 2026.
- Company expects to report clinical data from the Phase 2 BASECAMP pediatric DMD study in Q4 2026.
- Six-month interim data from TRAILHEAD Phase 2 adult DMD study showed reduced muscle fat fraction and increased total effort.
- R&D expenses increased to $9.6M in Q2 2026 from $4.4M in Q2 2025, primarily due to BASECAMP and TRAILHEAD studies.
Financial Impact
Net loss increased by $6.1M YoY in Q2 2026 to $11.7M; cash position strengthened by $34.1M to $61.8M from a $51.9M equity offering in February 2026.
Risk Factors
- Clinical trial failure or disappointing efficacy/safety data from BASECAMP or TRAILHEAD.
- Need for additional financing beyond 2027 if cash burn accelerates or trials are delayed.
- Competition from other DMD therapies, including gene therapies and exon-skipping drugs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005503 |
| Exhibit: exh_992.htm | 0001171843-26-005503 |
| Exhibit: exh_993.htm | 0001171843-26-005503 |
| Exhibit: exh_995.htm | 0001171843-26-005503 |
| Exhibit: exh_994.htm | 0001171843-26-005503 |
| Document: f6k_081126.htm | 0001171843-26-005503 |
| Document: 0001171843-26-005503-index-headers.html | 0001171843-26-005503 |
| Document: 0001171843-26-005503-index.html | 0001171843-26-005503 |
| Document: 0001171843-26-005503.txt | 0001171843-26-005503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.54 (+1.87%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers